Semaglutide Wegovy® - Tablet
US$ 24.65
glp-1 ckd Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes International Journal of Molecular Medicine
Description
C., Allen B
34 The trial had a total of 731 patients with a baseline mean A1C of 8.2% and a baseline total daily dose of insulin ranging from 56 to 62 units, depending on the treatment group
There are no side effects, only rapid progress
The main disadvantage is that evening hunger or cravings before bedtime may feel less suppressed compared to morning dosing
GIP: More powerful anti-inflammatory effects, making it a better choice for total metabolic balance
doi: 10.1001/jama.2021.1831
